MOUNJARO® 7.5mg KwikPen®, 1 Stk. (English Alternative)

MOUNJARO® 7.5mg KwikPen (English Alternative)

MOUNJARO® 7.5mg KwikPen (English Alternative) is Eli Lilly’s injectable tirzepatide, dosed at 7.5mg per 0.6ml as the intermediate titration strength between the 5mg and 10mg presentations. Tirzepatide is a dual GIP/GLP-1 receptor agonist indicated for type 2 diabetes and, in the markets where this variant circulates, chronic weight management. The English Alternative packaging is also sold in India, supplied as a multi-dose pre-filled KwikPen with four doses for once-weekly subcutaneous injection. Are you looking to buy MOUNJARO® 7.5mg KwikPen? Contact the Doctor Medica staff for guidance.

Product Specifications

• Brand: MOUNJARO®
• Active Substance: Tirzepatide
• Drug Class: Dual GIP and GLP-1 receptor agonist
• Manufacturer: Eli Lilly and Company Limited
• Strength:5mg per 0.6ml dose
• Pack Volume:4ml total, delivering four fixed 0.6ml doses (7.5mg per dose; 30mg per pen)
• Dosage Form: Solution for injection in multi-dose pre-filled KwikPen
• Pack Content: 1 pre-filled KwikPen with 4 doses
• Administration: Once weekly, subcutaneously
• Storage: Unopened, refrigerate at 2°C to 8°C (36°F to 46°F), do not freeze; in-use, store below 30°C (86°F) or refrigerated according to manufacturer guidelines
• Packaging: English version
• Availability: Also sold in India, in addition to other markets
• Weight: 60 grams
• Dimensions: Width: 60mm | Height: 40mm | Length: 150mm
• Prescription Status: Prescription-only pharmaceutical

What Is MOUNJARO® 7.5mg KwikPen (English)?

MOUNJARO® 7.5mg KwikPen is an injectable dual GIP/GLP-1 receptor agonist manufactured by Eli Lilly, supplied here in its English-language packaging variant, which is also sold in India and other markets that use English labeling. The English Alternative is a distributor pack presentation identified by its English-language labeling and intended market, not a separate regulatory product or a different formulation of tirzepatide.

Tirzepatide, the active substance, works differently from single-pathway GLP-1 agents: rather than acting on one receptor, it engages both the GIP and GLP-1 receptors independently, a first-in-class mechanism among approved incretin therapies [2]. Practitioners who buy weight loss products for chronic weight management will recognize tirzepatide as one of the injectable options in that category, distinct from the single-pathway agents.

Within Lilly’s titration schedule, the 7.5mg strength sits between 5mg and 10mg. This is the multi-dose KwikPen used in markets such as India, the UK, and the EU: one pen holds 2.4ml in total and delivers four fixed 0.6ml doses, each containing 7.5mg of tirzepatide, for once-weekly subcutaneous injection [1]. It should not be confused with the US single-dose auto-injector pen, which delivers a single dose per device; the KwikPen requires a separate needle to be attached for each injection.

English Alternative Packaging and International Markets

MOUNJARO® is marketed internationally, and legitimate products prepared for different jurisdictions can carry different carton layouts, regulatory text, and prescribing information. India is a significant market for the English Alternative presentation.

Eli Lilly first introduced MOUNJARO® in India on March 20, 2025, as single-dose starter vials, following authorization by the country’s national medicines regulator, the Central Drugs Standard Control Organisation (CDSCO), under the Ministry of Health and Family Welfare. The multi-dose MOUNJARO® KwikPen received CDSCO marketing authorization across all six strengths on June 26, 2025, and Eli Lilly rolled it out commercially across India in mid-August 2025, offering the 7.5mg strength alongside the 2.5mg, 5mg, 10mg, 12.5mg, and 15mg presentations [4].

Mechanism of Action

Tirzepatide is a dual GIP and GLP-1 receptor agonist built for once-weekly dosing, and its two receptor actions do different work. On the GLP-1 side, it supports glucose-dependent insulin secretion, curbs glucagon release, and slows gastric emptying, which together bring blood sugar levels down and flatten the peaks that follow meals. The GIP side contributes a further pathway for insulin response and metabolic regulation [2][3].

That combination is what carried tirzepatide past GLP-1 monotherapy in clinical trials, producing larger HbA1c reductions and more body-weight loss, with head-to-head data reported against semaglutide [2]. Since the effect is glucose-dependent, the standalone risk of low blood sugar stays relatively low, rising mainly when tirzepatide is paired with insulin or an insulin secretagogue. That pharmacology holds for every packaging variant, the English Alternative sold in India included.

Indications & Clinical Use

MOUNJARO® is approved as an adjunct to diet and exercise for glycemic control in adults with type 2 diabetes [3]. In markets such as India and across Europe, its label goes further, covering chronic weight management for adults with obesity (BMI ≥30 kg/m²), or overweight (BMI ≥27 kg/m²) with at least one weight-related comorbidity, again as an adjunct to diet and exercise [2]. That divergence is the reason to check the labeling for an English Alternative’s intended market: the approved wording that applies to a given pack depends on where it was authorized.

As an intermediate titration dose, 7.5mg is a step up rather than a starting point, reached once a patient has done well on 5mg and needs more glycemic or weight response. The pre-escalation review covers the usual ground: a doctor or pharmacist should look at how the patient has responded so far, gastrointestinal tolerability, other medicines in play, blood sugar levels, renal status, and any relevant comorbidities. Obstructive sleep apnoea is one of those comorbidities worth attention, since the weight loss on treatment can ease its severity and may call for respiratory support to be reassessed as therapy goes on [2]. Prescribers should confirm patient tolerance and glycemic or weight response before initiating or escalating to this step.

Administration & Injection Guidelines

MOUNJARO® is injected subcutaneously once weekly, at any time of day, with or without meals. Approved sites are the abdomen, thigh, and upper arm, rotated with each weekly dose to reduce injection-site reactions [3]. Because this is the multi-dose KwikPen rather than the US single-dose auto-injector, a fresh pen needle is attached for each administration. Pen needles are not included in the pack and must be supplied separately; the device accepts standard ISO 11608-2 pen needles (for example, 31G or 32G, 4mm–8mm).

• Attach a new needle, following the manufacturer’s Instructions for Use.
• Prime the pen ahead of the dose as directed.
• Dial or confirm the 7.5mg dose per the device instructions.
• Select and clean a site, then insert the needle and press the button.
• Hold for about 5 seconds until the dose window confirms delivery, then withdraw.

For storage, keep an unopened pen refrigerated at 2°C to 8°C (36°F to 46°F) and do not freeze; once in use, it may be held below 30°C (86°F) or refrigerated according to manufacturer guidelines. If a dose is missed, administer it as soon as possible within four days of the scheduled dose; if more than four days have passed, skip it and resume the weekly schedule rather than doubling up. The weekly dosing day can be changed when needed, provided at least three days separate two doses [5]. A pharmacist or nurse should counsel patients on needle attachment, priming, technique, storage, site rotation, and safe disposal at initiation and at any dose change.

Side Effects & Safety Considerations

Gastrointestinal effects are the most common: nausea, diarrhea, vomiting, decreased appetite, constipation, dyspepsia, and abdominal pain. They scale with the dose, peak when a patient is starting out or moving up a step, and for most people ease off as treatment settles [3].

Low blood sugar is a bigger risk once MOUNJARO® is paired with insulin or a sulfonylurea, so blood sugar levels warrant monitoring and the partner agent may need its dose adjusted. The rare but serious events to watch for are pancreatitis, acute gallbladder disease, and declining renal function when fluid loss follows severe GI symptoms, each one a reason for prompt assessment if it’s suspected. Serious hypersensitivity reactions, including anaphylaxis and angioedema, have also been reported.

None of this shifts with the packaging language, so for the full list of warnings and contraindications, licensed professionals should work from the current prescribing information for the relevant market [3].

Legal Status

MOUNJARO® is a prescription-only medicine containing tirzepatide, manufactured by Eli Lilly and Company Limited. Regulatory status is current as of July 2026 and depends on presentation and market. In the United States, the FDA first approved MOUNJARO® in 2022, supplied there as a single-dose auto-injector pen [3]. India authorized the KwikPen on June 26, 2025, ahead of its mid-August 2025 launch [4].

Because approvals and authorized indications vary by country, local requirements should be verified against current regional labeling. MOUNJARO® remains prescription-only, with supply restricted to licensed medical professionals.

MOUNJARO® KwikPen 7.5mg Price and Sourcing the English Alternative

The MOUNJARO® KwikPen 7.5mg price varies with the market of origin, packaging presentation, order quantity, and supply conditions, so the price of an English Alternative may differ from other presentations. When buying online, licensed professionals should verify the market of origin, manufacturer, batch documentation, expiry information, import requirements, and shipping and storage handling with their distributor to ensure product integrity.

Professionals who buy MOUNJARO® 7.5mg KwikPen wholesale, or who want to check for wholesale buying options across the authorized presentations, should distinguish among them carefully, since the MOUNJARO® KwikPen 7.5mg price, pack sizes, and packaging can differ by market. Those comparing the full strength range can also buy MOUNJARO® presentations through a licensed distributor.

Looking to buy MOUNJARO® 7.5mg KwikPen online or find information about the English Alternative? Contact Doctor Medica’s staff for guidance on product documentation and sourcing.

Citations and Resources

1. Eli Lilly and Company. Mounjaro KwikPen strengths and doses. https://www.lilly.com/en-CA/resources/faq/mounjaro-kwikpen/strengths-and-doses
2. European Medicines Agency. Mounjaro: EPAR — Product Information. 2024. https://www.ema.europa.eu/en/documents/product-information/mounjaro-epar-product-information_en.pdf
3. Eli Lilly and Company. Mounjaro (tirzepatide) injection, for subcutaneous use: US prescribing information. 2022. https://pi.lilly.com/us/mounjaro-uspi.pdf
4. ET Pharma. Lilly’s Mounjaro KwikPen gets CDSCO approval in India for type 2 diabetes and obesity care. The Economic Times. Published June 26, 2025. https://pharma.economictimes.indiatimes.com/news/drug-approvals-and-launches/lillys-mounjaro-kwikpen-gets-cdsco-approval-in-india-for-type-2-diabetes-and-obesity-care/122085790
5. Eli Lilly and Company. How to use, dosing & side effects | Mounjaro (tirzepatide). https://mounjaro.lilly.com/how-to-use-mounjaro